Work

Time to consider sequencing anti-inflammatory treatments with chemotherapy and immuno-stimulation?

Year: 2022

Type: article

Abstract: immunoediting, CDR3-antigen chemical complementarity scoring, granzyme B, immune checkpoint blockade, cancer and inflammation Paderi et al. (1) have shown that corticosteroid treatments soon after an ICB treatment, for several solid tumor types, have no impact on survival, but the same treatments delayed are associated with better progression-free survival.Possibly, after a certain period, TCR-cancer antigen interactions have subsided, and the remaining immune microenvironment only serves to facilitate tumor growth.

Source: Frontiers in Immunology

DOI: 10.3389/fimmu.2022.1082142

Author: George Blanck

Institutions: University of South Florida, Moffitt Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,950